Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Articles|April 14, 2020

Telepsychiatry Comes of Age, Reluctantly

Author(s)Chris Aiken, MD

Practical tips to help clinicians get started or to hone skills in telepsychiatry.

Chris Aiken, MD, provides practical tips to help clinicians get started or to hone their skills in telepsychiatry.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

digital vs print

Digital Amnesia and Why Print Should Be Prized

ByRonald W. Pies, MD

August 21st 2026

neuropsychiatry

Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome

August 19th 2026

Wearable-Derived Signals With the Strongest Evidence for Predicting Relapse in SMI

ByScott Fears, MD

August 4th 2026

How Wearable Tech Can Translate Into Practical Precision Medicine in Psychiatry

ByScott Fears, MD

August 4th 2026

fitbit

Bringing Wearable Data Into Psychiatric Care: Amae Health Partners With Google Health Enterprise to Improve Outcomes

August 4th 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Migraine and Psychiatric Comorbidities

Skin and Psych: Using Habit Loop Science to Interrupt the Itch-Scratch Cycle, With Judson Brewer, MD, PhD

Exploitation of Individuals With Psychosis

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment